ArticleAnnals of internal medicine2009
ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.
Lorraine L LipscombePubMed ↗Publisher ↗
No numbers read from the abstract.